risperidone has been researched along with Developmental Disabilities in 11 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results suggest that combination of atypical antipsychotic medications and pentoxifylline might have synergistic effects in treatment of behavioral problems of children with autism." | 9.14 | Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. ( Akhondzadeh, S; Fallah, J; Forghani, S; Ghanizadeh, A; Imani, R; Mohammadi, M; Mohammadi, MR; Mohebbi-Rasa, S; Raznahan, M; Rezazadeh, SA; Salehi, B, 2010) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 8.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| "Consumer satisfaction and social validity were measured during a double-blind, placebo-controlled evaluation of the atypical neuroleptic risperidone in treating severe aberrant behavior of persons with developmental disabilities." | 7.71 | Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures. ( Hellings, J; McAdam, DB; Napolitano, DA; Schroeder, SR; Zarcone, JR, 2002) |
| "Risperidone is a second-generation antipsychotic agent widely used in the treatment of schizophrenia and other psychotic disorders in adults." | 6.73 | Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ( Aman, MG; Lindsay, RL; Malone, K; Mannaert, E; Masty, J; Ramadan, Y; Remmerie, B; Vinks, AA, 2007) |
| "Risperidone was effective in reducing destructive behavior (compared to placebo) for 10 participants." | 5.32 | Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. ( Crosland, KA; Hellings, JA; Lindauer, SE; Matthew Reese, R; McKerchar, TL; Morse, PS; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2004) |
| "The results suggest that combination of atypical antipsychotic medications and pentoxifylline might have synergistic effects in treatment of behavioral problems of children with autism." | 5.14 | Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. ( Akhondzadeh, S; Fallah, J; Forghani, S; Ghanizadeh, A; Imani, R; Mohammadi, M; Mohammadi, MR; Mohebbi-Rasa, S; Raznahan, M; Rezazadeh, SA; Salehi, B, 2010) |
| " The Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities comprised academic clinicians with at least 10 years' experience in the field of mental retardation and developmental disabilities." | 4.82 | Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. ( Aman, MG; Gharabawi, GM, 2004) |
| " Among AAPDs, risperidone (RIS) ranked third after olanzapine (OLZ) and quetiapine (QUE) used during pregnancy, as OLZ is associated to substantial weight gain in adults and offspring." | 3.83 | Effects of prenatal exposure to antipsychotic risperidone on developmental neurotoxicity, apoptotic neurodegeneration and neurobehavioral sequelae in rat offspring. ( Singh, KP; Singh, M; Singh, MK, 2016) |
| " Under medication with clozapine he had experienced a single event of seizures which were due to hypocalcemia." | 3.74 | [22q11.2 deletion and schizophrenia in childhood and adolescence]. ( Briegel, W, 2007) |
| "Consumer satisfaction and social validity were measured during a double-blind, placebo-controlled evaluation of the atypical neuroleptic risperidone in treating severe aberrant behavior of persons with developmental disabilities." | 3.71 | Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures. ( Hellings, J; McAdam, DB; Napolitano, DA; Schroeder, SR; Zarcone, JR, 2002) |
| "We summarise preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone." | 3.70 | Research and treatment strategies in first-episode psychoses. The Pittsburgh experience. ( Haas, GL; Keshavan, MS; Pettegrew, JW; Schooler, NR; Sweeney, JA, 1998) |
| "Risperidone is a second-generation antipsychotic agent widely used in the treatment of schizophrenia and other psychotic disorders in adults." | 2.73 | Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. ( Aman, MG; Lindsay, RL; Malone, K; Mannaert, E; Masty, J; Ramadan, Y; Remmerie, B; Vinks, AA, 2007) |
| "Risperidone was effective in reducing destructive behavior (compared to placebo) for 10 participants." | 1.32 | Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. ( Crosland, KA; Hellings, JA; Lindauer, SE; Matthew Reese, R; McKerchar, TL; Morse, PS; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, KP | 1 |
| Singh, MK | 1 |
| Singh, M | 1 |
| Akhondzadeh, S | 1 |
| Fallah, J | 1 |
| Mohammadi, MR | 1 |
| Imani, R | 1 |
| Mohammadi, M | 1 |
| Salehi, B | 1 |
| Ghanizadeh, A | 1 |
| Raznahan, M | 1 |
| Mohebbi-Rasa, S | 1 |
| Rezazadeh, SA | 1 |
| Forghani, S | 1 |
| Zarcone, JR | 2 |
| Lindauer, SE | 1 |
| Morse, PS | 1 |
| Crosland, KA | 1 |
| Valdovinos, MG | 1 |
| McKerchar, TL | 1 |
| Matthew Reese, R | 1 |
| Hellings, JA | 1 |
| Schroeder, SR | 2 |
| Aman, MG | 2 |
| Gharabawi, GM | 1 |
| Ivanov, I | 1 |
| Klein, M | 1 |
| Green, WH | 1 |
| Coffey, B | 1 |
| Vinks, AA | 1 |
| Remmerie, B | 1 |
| Mannaert, E | 1 |
| Ramadan, Y | 1 |
| Masty, J | 1 |
| Lindsay, RL | 1 |
| Malone, K | 1 |
| Briegel, W | 1 |
| Hardan, A | 1 |
| Johnson, K | 1 |
| Johnson, C | 1 |
| Hrecznyj, B | 1 |
| Keshavan, MS | 1 |
| Schooler, NR | 1 |
| Sweeney, JA | 1 |
| Haas, GL | 1 |
| Pettegrew, JW | 1 |
| Demb, HB | 1 |
| Nguyen, KT | 1 |
| McAdam, DB | 1 |
| Hellings, J | 1 |
| Napolitano, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CYP2D6 PHARMACOGENETICS IN RISPERIDONE-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHIATRIC OR NEURODEVELOPMENTAL DISORDERS[NCT00783783] | 47 participants (Actual) | Observational | 2008-11-30 | Completed | |||
| Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors[NCT00065273] | Phase 3 | 50 participants | Interventional | 1998-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for risperidone and Developmental Disabilities
| Article | Year |
|---|---|
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia Dise | 2004 |
3 trials available for risperidone and Developmental Disabilities
| Article | Year |
|---|---|
Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.
Topics: Antipsychotic Agents; Autistic Disorder; Behavioral Symptoms; Child; Child, Preschool; Developmental | 2010 |
Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.
Topics: Adolescent; Antipsychotic Agents; Area Under Curve; Child; Child, Preschool; Cytochrome P-450 CYP2D6 | 2007 |
Case study: risperidone treatment of children and adolescents with developmental disorders.
Topics: Adolescent; Antipsychotic Agents; Child; Comorbidity; Developmental Disabilities; Dose-Response Rela | 1996 |
7 other studies available for risperidone and Developmental Disabilities
| Article | Year |
|---|---|
Effects of prenatal exposure to antipsychotic risperidone on developmental neurotoxicity, apoptotic neurodegeneration and neurobehavioral sequelae in rat offspring.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Annexin A5; Antipsychotic Agents; Apop | 2016 |
Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis.
Topics: Adult; Aggression; Antipsychotic Agents; Child; Developmental Disabilities; Female; Humans; Male; Ra | 2004 |
The challenges of psychopharmacological management of children with severe developmental disabilities.
Topics: Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Caregivers; Child; Developmental Disabilit | 2006 |
[22q11.2 deletion and schizophrenia in childhood and adolescence].
Topics: Adolescent; Antipsychotic Agents; Calcium; Child; Chromosome Deletion; Chromosomes, Human, Pair 22; | 2007 |
Research and treatment strategies in first-episode psychoses. The Pittsburgh experience.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain Diseases; Developmental Disabilities; Episode of Care | 1998 |
Movement disorders in children with developmental disabilities taking risperidone.
Topics: Adolescent; Antipsychotic Agents; Child; Developmental Disabilities; Dyskinesia, Drug-Induced; Femal | 1999 |
Effects of risperidone on aberrant behavior in persons with developmental disabilities: II. Social validity measures.
Topics: Adolescent; Adult; Antipsychotic Agents; Behavior; Caregivers; Child; Consumer Behavior; Cross-Over | 2002 |